RECURRENT subarrachnoid haemorrhage from intrachanial aneurysms most commonly occurs during the 2nd, 3rd and 4th weeks after the initial ictus, and after 8 weeks the recurrence rate, approaching 50% in untreated cases, falls sharply (Hamby, 1948; Walton, 1952; Holmes, 1957; McKissoch, Paine & Walshe, 1958) .
For those patients having no surgery who survive 6 weeks after subarachnoid haemorrhage, the chances of surviving 1 year or longer are 82% (Locksley, 1966) .
The anatomical pattern of saccular aneurysm is too often repeated, at each of the common sites, for any one to be recognized as more vulnerable to recurrent bleeding than others. Mechanical factors such as the size of aneurysm, streaming, or width and configuration of the neck, do not in general influence the recurrence rate; and our attention is necessarily directed towards variations in the natural physico-chemical processes believed first to seal, and then to repair, a rent in a blood vessel.
The primary sealing of the hole in an aneurysm wall by a platelet plug, at first permeable to red cells, may be assumed responsible for the initial stemming of the leak within, say, 4 min. Cells infiltrate the plug and the complex process of building a clot commences.
What happens to this clot during the next 8 weeks determines whether the patient suflers recurrent haemorrhage. In about half such patients the seal remains viable; good firm adherent clot becomes organized, and the repair may last for many years. In a conservatively treated series of cases there must be a very fine dividing-line between the mechanism of blood clotting in these patients, and in the other 50% whose aneurysms bleed again within a few weeks. This does not mean that there is any recognizable abnormality in the maturation of the clot in those cases that bleed again. Clotting and bleeding times in both groups are within normal limits; but the balance is so delicate that either variations within the norm are decisive, or some other factor is operative in the maturation of clot, which we have not been able to measure sufficiently accurately. Platelet adhesiveness, blood viscosity, local fibrinogen concentration, fibrinolysis-any or all of these may be relevant. It seems certain, however, that there is both continual building up and absorption of clot going on simultaneously-the laying down of fibrin and formed elements on the one hand, and fibrinolysis with digestion on the other. Perhaps one of these processes ceases too soon, or another too late. Hellem (1960) says that 'the fact that Factor R is inactivated in plasma (in vitro and probably in vivo) may, with the fibrinolytic system, explain why a thrombus does not grow indefinitely'.
Two considerations prompted the investigation in this paper: in the first place the development of accurate methods of fibrinolysis assay in vitro, and secondly the marketing of epsilon aminocaproic acid (EACA), known to inhibit fibrinolysis and almost harmless when given orally.
Between November 1963 and March 1965 assay of plasminogen activator and of fibrinogen was performed in 109 cases of subarachnoid haemorrhage admitted to the South East Regional Neurosurgical Centre. A clinical trial of the effects of administering EACA was continued until the end of the year.
Methods
The large number of patients in the series and the length of the chemical estimations precluded their use for the assay of both fibrinogen and plasminogen.
Fibrinogen was therefore measured by the fibrinogen titre, using doubling dilution of plasma clotted with 50 units/ml thrombin. Preliminary experiments showed that a titre of 1 /128 corresponded to more than 100 mg of fibrinogen.
Plasminogen was assayed by the streptokinase activated fibrinolysis time, using the method of Innes & Sevitt (1964) . The normal range is 1-2-hr. Comparison of this method and a caseinolytic method showed that this range corresponded to 7. R. Gibbs and P. O'Gormnan about 40-140 mg/ 100 ml plasminogen, with close correlation between the methods.
The dilute whole blood clot lysis time described by Fearnley, Balmforth & Fearnley (1957) The investigation as far as aneurysms are concerned is divided into two parts: Part I-The relation between lysis times and the predictability of recurrent haemorrhage. Part II-The effects of administration of EACA on the diluted whole blood clot lysis times and on the frequency of recurrent haemorrhage. Sixty-four patients were given 12 g EACA three times daily for a maximum of 28 days. The intravenous route was employed in a few instances, in unconscious patients.
There were studied twenty-two patients with berry aneurysms, to whom no EACA was administered. Twelve of these had aneurysms of the internal carotid artery, treated successfully by permanent carotid occlusion. The lowest lysis times recorded were 3 5 hr (one case) and 3 8 hr (two cases). The remaining nine cases had com- With the exception of the one case mentioned above, the lysis times were all prolonged when EACA was being given, usually to more than 24 hr and often to 48 hr; the time rapidly returned to normal if the patient vomited the drug. The streptokinase-activated lysis times were all prolonged, but this was only a reflection of the inactivation of the streptokinase by EACA. Fibrinogen was present in normal quantities in all cases.
Complications
Patients experience some difficulty in tolerating the drug in any form by mouth, in doses of 36 g daily. Much the commonest complication was nausea, which inconvenienced about three-quarters of the patients, and occasionally led to loss of a dose by vomiting. Few patients prefer chewing the granules to a watery solution, and all said that the syrup was sickly. The Of special interest should be the lysis times of those patients who have several haemorrhages within a few weeks. Cases 1, 3 and 8 all had three haemorrhages within 16 days, but only in the first was the lysis time very short (+ hr before death).
Though no unequivocal evidence emerges that treatment by EACA alone protects aneurysms from repeated bleeding, recurrence may prove to be less likely if the whole-blood-clot lysis times can be raised consistently to the level of 40 hr (Tables 2-5 ).
The extended clinical trial provided no conclusive evidence that the administration of EACA in the doses given alters the prognosis in subarachnoid haemorrhage.
In spite of the equivocal findings in this preliminary investigation, we are convinced that the 
